Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers

Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers

Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector vaccine (ChAdOx1) have been widely used in resource-limited settings. However, the information on the reactogenicity and immunogenicity of these two vaccines in the same setting are limited. Healthy health care workers (HCWs) aged 18 y...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine: X 2022-04, Vol.10, p.100153-100153, Article 100153
Main Authors: Angkasekwinai, Nasikarn, Sewatanon, Jaturong, Niyomnaitham, Suvimol, Phumiamorn, Supaporn, Sukapirom, Kasama, Sapsutthipas, Sompong, Sirijatuphat, Rujipas, Wittawatmongkol, Orasri, Senawong, Sansnee, Mahasirimongkol, Surakameth, Trisiriwanich, Sakalin, Chokephaibulkit, Kulkanya
Format: Article
Language:eng
Subjects:
ChAdOx1
CoronVac
Heath care workers
Immunogenicity
Regular paper
Thailand
Variant of concern
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector vaccine (ChAdOx1) have been widely used in resource-limited settings. However, the information on the reactogenicity and immunogenicity of these two vaccines in the same setting are limited. Healthy health care workers (HCWs) aged 18 years or older were randomly assigned to receive either two doses of CoronaVac at 4 weeks interval or two doses of ChAdOx1 at 10 weeks interval. Self-reported adverse events (AEs) were collected for 7 days following each vaccination. Immunogenicity was determined by IgG antibodies levels against receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S1 subunit) and the 50% plaque reduction neutralization titers against various strains. Of the 360 HCWs, 180 in each vaccine group, the median (interquartile range: IQR) age was 35 (29–44) years old and 84.2% were female. Participants who received ChAdOx1 reported higher frequency of AEs than those received CoronaVac after both the first dose (84.4% vs. 66.1%, P 
ISSN:2590-1362
2590-1362